Literature DB >> 18295938

Mouse models for the study of mucosal vaccination against otitis media.

Albert Sabirov1, Dennis W Metzger.   

Abstract

Otitis media (OM) is one of the most common infectious diseases in humans. The pathogenesis of OM involves nasopharyngeal (NP) colonization and retrograde ascension of the pathogen up the Eustachian tube into the middle ear (ME). Due to increasing rates of antibiotic resistance, there is an urgent need for vaccines to prevent infections caused by the most common causes of bacterial OM, including nontypeable Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Current vaccine strategies aim to diminish bacterial NP carriage, thereby reducing the likelihood of developing acute OM. To be effective, vaccination should induce local mucosal immunity both in the ME and in the NP. Studies in animal models have demonstrated that the intranasal route of vaccination is particularly effective at inducing immune responses in the nasal passage and ME for protection against OM. The mouse is increasingly used in these models, because of the availability of murine reagents and the existence of technology to manipulate murine models of disease immunologically and genetically. Previous studies confirmed the suitability of the mouse as a model for inflammatory processes in acute OM. Here, we discuss various murine models of OM and review the applicability of these models to assess the efficacy of mucosal vaccination and the mechanisms responsible for protection. In addition, we discuss various mucosal vaccine antigens, mucosal adjuvants and mucosal delivery systems.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18295938      PMCID: PMC2323831          DOI: 10.1016/j.vaccine.2008.01.029

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  195 in total

1.  Cutting edge: dichotomy of homing receptor dependence by mucosal effector B cells: alpha(E) versus L-selectin.

Authors:  K L Csencsits; N Walters; D W Pascual
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

2.  IgA production without mu or delta chain expression in developing B cells.

Authors:  A J Macpherson; A Lamarre; K McCoy; G R Harriman; B Odermatt; G Dougan; H Hengartner; R M Zinkernagel
Journal:  Nat Immunol       Date:  2001-07       Impact factor: 25.606

3.  Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci.

Authors:  R Malley; M Lipsitch; A Stack; R Saladino; G Fleisher; S Pelton; C Thompson; D Briles; P Anderson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 4.  Mucosal immunity and viral infections.

Authors:  J Freihorst; P L Ogra
Journal:  Ann Med       Date:  2001-04       Impact factor: 4.709

5.  Intranasal immunization enhances clearance of nontypeable Haemophilus influenzae and reduces stimulation of tumor necrosis factor alpha production in the murine model of otitis media.

Authors:  A Sabirov; S Kodama; T Hirano; M Suzuki; G Mogi
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

6.  Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells.

Authors:  K A Benton; J A Misplon; C Y Lo; R R Brutkiewicz; S A Prasad; S L Epstein
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

7.  Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections.

Authors:  V C Huber; J M Lynch; D J Bucher; J Le; D W Metzger
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

Review 8.  Neonatal and early life vaccinology.

Authors:  C A Siegrist
Journal:  Vaccine       Date:  2001-05-14       Impact factor: 3.641

9.  Recombinant PhpA protein, a unique histidine motif-containing protein from Streptococcus pneumoniae, protects mice against intranasal pneumococcal challenge.

Authors:  Y Zhang; A W Masi; V Barniak; K Mountzouros; M K Hostetter; B A Green
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

Review 10.  Lactic acid bacteria as live vaccines.

Authors:  A Mercenier; H Müller-Alouf; C Grangette
Journal:  Curr Issues Mol Biol       Date:  2000-01       Impact factor: 2.081

View more
  14 in total

1.  Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis.

Authors:  Maowei Wang; Yan Yue; Chunsheng Dong; Xiaoyun Li; Wei Xu; Sidong Xiong
Journal:  Clin Vaccine Immunol       Date:  2013-09-11

Review 2.  Panel 5: Microbiology and immunology panel.

Authors:  Timothy F Murphy; Tasnee Chonmaitree; Stephen Barenkamp; Jennelle Kyd; Johanna Nokso-Koivisto; Janak A Patel; Terho Heikkinen; Noboru Yamanaka; Pearay Ogra; W Edward Swords; Tania Sih; Melinda M Pettigrew
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

Review 3.  Animal models of Streptococcus pneumoniae disease.

Authors:  Damiana Chiavolini; Gianni Pozzi; Susanna Ricci
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

Review 4.  Mouse models for human otitis media.

Authors:  Dennis R Trune; Qing Yin Zheng
Journal:  Brain Res       Date:  2009-03-06       Impact factor: 3.252

Review 5.  Innate Immunity: Orchestrating Inflammation and Resolution of Otitis Media.

Authors:  Arwa Kurabi; Kwang Pak; Allen F Ryan; Stephen I Wasserman
Journal:  Curr Allergy Asthma Rep       Date:  2016-01       Impact factor: 4.806

Review 6.  What have we learned from murine models of otitis media?

Authors:  Hayley E Tyrer; Michael Crompton; Mahmood F Bhutta
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.806

Review 7.  Serotype-independent pneumococcal vaccines.

Authors:  Eliane Namie Miyaji; Maria Leonor Sarno Oliveira; Eneas Carvalho; Paulo Lee Ho
Journal:  Cell Mol Life Sci       Date:  2012-12-27       Impact factor: 9.261

Review 8.  Molecular aspects of Moraxella catarrhalis pathogenesis.

Authors:  Stefan P W de Vries; Hester J Bootsma; John P Hays; Peter W M Hermans
Journal:  Microbiol Mol Biol Rev       Date:  2009-09       Impact factor: 11.056

9.  Comprehensive antigen screening identifies Moraxella catarrhalis proteins that induce protection in a mouse pulmonary clearance model.

Authors:  Margarita Smidt; Patrick Bättig; Suzanne J C Verhaegh; Axel Niebisch; Markus Hanner; Sanja Selak; Wolfgang Schüler; Eva Morfeldt; Christel Hellberg; Eszter Nagy; Urban Lundberg; John P Hays; Andreas Meinke; Birgitta Henriques-Normark
Journal:  PLoS One       Date:  2013-05-09       Impact factor: 3.240

10.  Deletion of the complement C5a receptor alleviates the severity of acute pneumococcal otitis media following influenza A virus infection in mice.

Authors:  Hua Hua Tong; Garrett Lambert; Yong Xing Li; Joshua M Thurman; Gregory L Stahl; Kelsey Douthitt; Caitlin Clancy; Yujuan He; Andrew S Bowman
Journal:  PLoS One       Date:  2014-04-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.